Management of EGFR mutated nonsmall cell lung carcinoma patients
Explore this paper's citation graph
Summary
EGFR TKIs have a favourable impact on progression-free survival when given as first line treatment in mutated patients, but may also have a moderate effect as a salvage therapy and in maintenance in an unselected population.
- Type
- article
- Published
- 2015-02-19
- Cited by
- 35
- References
- 94
- Access
- Open access
- OpenAlex
- https://openalex.org/W25700389
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5378189
Keywords
Theology, Art, Philosophy
References
- Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
- Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
- Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
- Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
- Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study
- Detection of PCR products using self-probing amplicons and fluorescence
- A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
- A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.
- Untangling the ErbB signalling network
- Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
- Erlotinib in lung cancer - molecular and clinical predictors of outcome.
- Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
- Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
- EGF–ERBB signalling: towards the systems level
- Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
- Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
- Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Cited by
- Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques
- The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinib.
- Epidermal growth factor receptor (EGFR) in the era of Precision Medicine: The tale of a perfect example of targeted therapy. A review
- Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.
- Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
- A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer
- [Inhaled chemotherapy - Part 2: Clinical practice and potential applications].
- Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
- Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.
- Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
- Using Artificial Intelligence (Watson for Oncology) for Treatment Recommendations Amongst Chinese Patients with Lung Cancer: Feasibility Study
- Contextual Classifications of Cancer Driver Genes
- Somatic selection distinguishes oncogenes and tumor suppressor genes
- Validation of the eighth edition clinical T categorization system for clinical stage IA resected lung adenocarcinomas: Prognostic implications of the ground-glass opacity component.
- The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
- Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature
- Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review
- EGFR and non-small cell lung cancer: implications for surgical practice
- Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
- Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer
Related papers
No related papers recorded.